Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 15, 2026

Earnings week ahead: WMT, ET. OXY, PANW, NEM, MDT, DVN, DE, ETSY, CVNA, and more

View original at seekingalpha.com
Earnings week ahead: WMT, ET…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OXY trades at a sector premium despite falling toward $40, supported largely by the perceived Buffett put. Earnings remain under pressure with the stock trading at ~30x 2026 EPS and free cash flow yields trailing peers such as Devon Energy. The $9.7B OxyChem sale to Berkshire Hathaway strengthens liquidity and supports debt reduction but does not fully offset lower forward earnings, leaving valuation and leverage as key overhangs.

    80% confidence
  • PANW stock warrants a Sell rating due to premium valuation and signs of slowing momentum. Next-generation ARR growth decelerated to 29% from 32%. Management guidance for Q2 and FY26 implies further slowing across revenue, RPO, and next-gen ARR. Additional headwinds include DRAM pricing pressures and China-related restrictions.

    80% confidence
  • While Walmart has demonstrated exceptional long-term performance (~520% total return over the past decade, far outpacing the S&P 500), fundamentals no longer justify the premium. WMT now trades at valuation multiples exceeding peers such as Amazon, Alphabet, Meta, and even Nvidia, raising the risk of multiple compression if growth remains in the mid-single digits.

    80% confidence
  • Seeking Alpha Quant Rating on WMT is Hold, reflecting valuation concerns.

    80% confidence
  • Seeking Alpha Quant Rating on OXY is Hold, broadly aligning with sell-side caution around near-term growth.

    80% confidence
  • Seeking Alpha Quant Rating on PANW stands at Hold.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com